Other languages Portage Biotech Inc.

Equities

PRTG

VGG7185A1286

Market Closed - Nasdaq Other stock markets 02:00:00 04/05/2024 am IST			5-day change	1st Jan Change
0.271 ^USD	+4.27%		+14.35%	-85.11%

15/04	Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives	CI
12/04	Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives	15/04
Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives	12/04
Portage Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	29/02
Portage Biotech to Pause Drug Development in PORT-2 iNKT Program, to Cut Workforce	05/01
Portage Biotech to Evaluate Range of Strategic Options	04/01
Portage Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	29/11
Portage Biotech Inc. Presents Updates on its iNKT and Adenosine Programs at the Society for Immunotherapy of Cancer's 38th Annual Meeting	06/11
Portage Biotech Inc. Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with Keytruda®? (Pembrolizumab) in Solid Tumors	05/23/05
Portage Biotech Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	30/23/30
Portage Biotech Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	01/23/01
Portage Biotech Inc. Announces First Patient Dosed in Phase 1A Trial of Portage-6 in Select Solid Tumors	26/23/26
Portage Biotech Reports Updated Interim Data for Lead Inkt Engager, Port-2, in A Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer At the 2023 American Society for Clinical Oncology Annual Meeting	05/23/05
Portage Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	01/23/01
Portage Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	30/22/30
Portage Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	30/22/30
Portage Biotech Inc. Presents Updated Data on the Phase 1/2 Trial Evaluating Port-2 At the Society for Immunotherapy of Cancer’S 37Th Annual Meeting	10/22/10
Portage Biotech, Merck to Collaborate on Cancer Study	08/22/08
Portage Biotech Inc. Announces Clinical Trial Collaboration Agreement with Merck	08/22/08
Portage Biotech Inc. Provides Research and Development Update	14/22/14
Portage Biotech Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	30/22/30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Portage Biotech Inc.

Equities

PRTG

VGG7185A1286

Other languages

Filters